Use of Atypical Antipsychotics in the Treatment of Autistic Disorder

  title={Use of Atypical Antipsychotics in the Treatment of Autistic Disorder},
  author={Joan M. Stachnik and Cheryl L Nunn-Thompson},
  journal={Annals of Pharmacotherapy},
  pages={626 - 634}
Objective: To review clinical trials and reports describing the efficacy and safety of atypical antipsychotics (olanzapine, ziprasidone, quetiapine, aripiprazole) in the treatment of autistic or other pervasive developmental disorders. Data Sources: English-language publications from the MEDLINE database (1966–February 2007) including clinical trials, case reports, and retrospective series were reviewed. Study Selection and Data Extraction: Relevant data were extracted from studies of selected… 

Tables from this paper

Aripiprazole in patients with autistic spectrum disorders: a review and case reports

APZ reduces aggression in ASDs and improves qualitative deficits in interpersonal interactions and motivation and causes fewer adverse events compared with other antipsychotics.

Atypical and Typical Antipsychotics in the Schools.

Although these agents, as their name suggests, are most commonly used to alleviate positive, as well as some negative, symptoms of psychotic manifestations, empirical evidence has suggested their efficacy in the treatment of other presentations.

Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a meta-analysis.

  • Akanksha SharmaS. Shaw
  • Psychology, Medicine
    Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners
  • 2012

Pharmacological Treatment of Autism

Evidence from controlled studies indicates that the atypical antipsychotic drug risperidone is frequently effective for ameliorating symptoms of irritability, hyperactivity, social withdrawal, and stereotypic, repetitive behavior.

Quetiapine abuse and dependence in psychiatric patients: a systematic review of 25 case reports in the literature

Quetiapine is likely to be abused by male psychiatric patients in their mid-thirties and less than 50% of them having positive history of substance abuse/dependence, suggesting close monitoring for drug misuse is needed in the course of the entire treatment period.

Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Irritability in Autistic Children

  • E. Kirino
  • Psychology, Medicine
    Clinical medicine insights. Pediatrics
  • 2014
Head-to-head comparison studies are needed to support that aripiprazole may be a promising drug that can be used to treat irritability in autistic children, and risperidone has the greatest amount of evidence supporting it, including randomized controlled trials; thus, its efficacy and tolerance has been established in comparison with other agents.

Control of psychomotor agitation and aggressive behavior in patients with autistic disorder: a retrospective chart review.

Second-generation antipsychotics seem to reduce psychomotor agitation and aggressive behavior in patients with autistic spectrum disorder; however, further studies are required to evaluate the side effects of these drugs in relation to their beneficial effects.

Antipsychotics for Children and Young Adults: A Comparative Effectiveness Review

This is the first comprehensive review comparing the effectiveness and safety across the range of antipsychotics for children and young adults and found some SGAs have a better side effect profile than other SGAs.

Buspirone for Autistic Disorder in a Woman with an Intellectual Disability

The reduction in target aggressive behaviors achieved with buspirone therapy allowed other treatment interventions to proceed more effectively in the patient, and Clinicians may wish to consider use of busPirone in patients with AD who do not respond to or have risk factors (or use of other therapy).

Treating pediatric patients with antipsychotic drugs: balancing benefits and safety.

This article reviews the current trends for the therapeutic use of antipsychotic medications in pediatric psychiatry and the available data that support their efficacy, but it also discusses important issues related to their safety during both short-term and long-term administration.



Second-generation antipsychotic medications in children and adolescents.

Evidence suggests that second-generation antipsychotics are efficacious in the treatment of psychosis, bipolar disorders, pervasive developmental disorders, and Tourette's Disorder, and are potentially useful in mental retardation, conduct disorder, and severe attention deficit hyperactivity disorder.

Risperidone in children with autism and serious behavioral problems.

Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder and the benefit was maintained at six months.

Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.

The findings suggest that olanzapine is a promising treatment for children with autistic disorder and further placebo-controlled and long-term studies of olanZapine in autistic disorder are required.

Open-Label Study of Olanzapine in Children with Pervasive Developmental Disorder

Olanzapine was a relatively safe medication in children, its clinical relevance in children with pervasive developmental disorder may be limited, and three children showed extrapyramidal symptoms that disappeared after the dose was lowered.

Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series

Aripiprazole was well tolerated and effective in each of the cases and appears to be a safe and efficacious alternative in the management of patients with both intellectual disabilities and schizophrenia.

Treating Functional Impairment of Autism with Selective Serotonin-Reuptake Inhibitors

Benefits with SSRIs in treating functional impairments in autism have been observed and current evidence does not support selection of one SSRI over another for any impairment associated with autism.

Quetiapine in nine youths with autistic disorder.

The data suggest that quetiapine may not be a particularly effective agent in the treatment of adolescent patients with AD, and it seems reasonable that they be conducted with more rigor, less treatment-resistant cohorts, and, possibly, a different dosing strategy.

A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders.

Quetiapine was modestly effective for maladaptive behavior in patients with a PDD.

The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment.

In adults with autism, a switch to ziprasidone from other atypical antipsychotics appears to have the potential for maintaining beneficial effect on behavior while improving major health indices including weight and lipid levels.

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.

Preliminary results suggest that olanzapine may be an effective and well tolerated drug in targeting core and related symptoms of PDDs in children, adolescents, and adults.